Aspects of Gene Therapy Products Using Current Genome-Editing Technology in Japan.

double-strand break gene therapy genome editing off-target effect on-target mutagenesis safety

Journal

Human gene therapy
ISSN: 1557-7422
Titre abrégé: Hum Gene Ther
Pays: United States
ID NLM: 9008950

Informations de publication

Date de publication:
10 2020
Historique:
pubmed: 1 8 2020
medline: 24 8 2021
entrez: 1 8 2020
Statut: ppublish

Résumé

The development of genome-editing technology could lead to breakthrough gene therapy. Genome editing has made it possible to easily knock out or modify a target gene, while current gene therapy using a virus vector or plasmid hampering modification with respect to gene replacement therapies. Clinical development using these genome-editing tools is progressing rapidly. However, it is also becoming clear that there is a possibility of unintended gene sequence modification or deletion, or the insertion of undesired genes, or the selection of cells with abnormalities in the cancer suppressor gene

Identifiants

pubmed: 32731837
doi: 10.1089/hum.2020.156
pmc: PMC7585607
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1043-1053

Références

Nat Biotechnol. 2015 Feb;33(2):187-197
pubmed: 25513782
Science. 2013 Oct 11;342(6155):253-7
pubmed: 24115442
Nat Commun. 2019 Sep 30;10(1):4439
pubmed: 31570731
PLoS One. 2015 Sep 09;10(9):e0136644
pubmed: 26351841
J Biol Chem. 2014 Aug 1;289(31):21312-24
pubmed: 24907273
Nat Commun. 2017 Apr 07;8:14958
pubmed: 28387220
Nat Biotechnol. 2015 Sep;33(9):985-989
pubmed: 26121415
Genetics. 2011 Aug;188(4):773-82
pubmed: 21828278
Cell Stem Cell. 2014 Jul 3;15(1):31-6
pubmed: 24996168
Nat Methods. 2012 Jul 01;9(8):805-7
pubmed: 22751204
Nat Med. 2018 Jul;24(7):939-946
pubmed: 29892062
Nucleic Acids Res. 2015 Jun 23;43(11):5560-71
pubmed: 25964300
Nat Rev Cancer. 2018 Nov;18(11):696-705
pubmed: 30293088
Nat Biotechnol. 2008 Jul;26(7):808-16
pubmed: 18587387
Genome Med. 2016 Nov 15;8(1):120
pubmed: 27846896
Oncogene. 2001 Sep 10;20(40):5572-9
pubmed: 11607810
Mol Cell. 2012 Aug 24;47(4):497-510
pubmed: 22920291
Blood. 2017 Jul 20;130(3):285-296
pubmed: 28539325
Front Genet. 2019 Jan 07;9:691
pubmed: 30687381
Nat Biotechnol. 2018 Sep;36(8):765-771
pubmed: 30010673
Biotechnol Adv. 2017 Jan - Feb;35(1):95-104
pubmed: 28011075
Mol Ther Methods Clin Dev. 2018 Jun 15;10:105-112
pubmed: 30073181
Nat Methods. 2016 Oct;13(10):868-74
pubmed: 27595405
Sci Rep. 2017 Nov 9;7(1):15189
pubmed: 29123154
Oncotarget. 2016 Sep 13;7(37):60535-60554
pubmed: 27528034
Nature. 2015 Nov 12;527(7577):192-7
pubmed: 26375006
Cell Stem Cell. 2014 Jul 3;15(1):27-30
pubmed: 24996167
Nat Methods. 2017 Jun;14(6):607-614
pubmed: 28459458
Genome Res. 2013 Jun;23(6):1008-17
pubmed: 23478401
Genome Res. 2010 Jan;20(1):81-9
pubmed: 19952142
Nat Biotechnol. 2015 Jan;33(1):73-80
pubmed: 25357182
Adv Exp Med Biol. 2017;1016:29-42
pubmed: 29130152
Sci Rep. 2015 Jul 28;5:12281
pubmed: 26216318
Nucleic Acids Res. 2013 Aug;41(14):e141
pubmed: 23748566
Sci Rep. 2016 Aug 17;6:31666
pubmed: 27530713
Nat Med. 2015 Feb;21(2):121-31
pubmed: 25654603
Genome Res. 2009 Jul;19(7):1279-88
pubmed: 19470664
Nat Biotechnol. 2017 Dec;35(12):1179-1187
pubmed: 29131148
Science. 2011 Sep 30;333(6051):1843-6
pubmed: 21960622
Nature. 2016 Apr 20;533(7603):420-4
pubmed: 27096365
Genome Biol. 2018 Nov 6;19(1):187
pubmed: 30400938
Science. 2016 Sep 16;353(6305):
pubmed: 27492474
Genetics. 2015 Dec;201(4):1295-306
pubmed: 26482793
Nucleic Acids Res. 2013 Oct;41(19):9049-61
pubmed: 23907390
Sci Rep. 2017 Aug 24;7(1):9363
pubmed: 28839205
Nat Med. 2018 Jul;24(7):927-930
pubmed: 29892067
Genome Res. 2016 Mar;26(3):406-15
pubmed: 26786045
Science. 2014 Jan 3;343(6166):80-4
pubmed: 24336569
PLoS One. 2018 Jan 29;13(1):e0185987
pubmed: 29377933
Nature. 2019 Feb;566(7742):105-109
pubmed: 30675057
Sci Rep. 2018 Mar 27;8(1):5272
pubmed: 29588483
Cell. 2014 Oct 23;159(3):647-61
pubmed: 25307932
Science. 2013 Feb 15;339(6121):823-6
pubmed: 23287722
Cell. 1983 May;33(1):25-35
pubmed: 6380756
PLoS One. 2017 Jan 17;12(1):e0169931
pubmed: 28095454
PLoS One. 2014 Jan 20;9(1):e85755
pubmed: 24465685
Cell Stem Cell. 2014 Jul 3;15(1):12-3
pubmed: 24996165
Science. 2003 Oct 17;302(5644):415-9
pubmed: 14564000
Nat Biotechnol. 2013 Aug;31(8):688-91
pubmed: 23929339
Mol Ther. 2016 Sep;24(9):1561-9
pubmed: 27406980
Nat Methods. 2015 Mar;12(3):237-43, 1 p following 243
pubmed: 25664545
Nat Med. 2019 Feb;25(2):249-254
pubmed: 30692695
Science. 2013 Feb 15;339(6121):819-23
pubmed: 23287718
Blood. 2015 Apr 23;125(17):2597-604
pubmed: 25733580
Int J Pharm. 2015 Oct 15;494(1):180-94
pubmed: 26278489
Nat Methods. 2017 Jun;14(6):600-606
pubmed: 28459459
Nat Commun. 2014 Jun 03;5:3964
pubmed: 24888982
Blood. 2016 May 26;127(21):2546-52
pubmed: 27053530
Nature. 2016 Dec 1;540(7631):144-149
pubmed: 27851729

Auteurs

Teruhide Yamaguchi (T)

Kanazawa Institute of Technology, Ishikawa, Japan.
Nihon Pharmaceutical University.

Eriko Uchida (E)

National Institute of Health Sciences.

Takashi Okada (T)

The University of Tokyo.

Keiya Ozawa (K)

Jichi Medical University.

Masafumi Onodera (M)

National Center for Child Health and Development.

Akihiro Kume (A)

Jichi Medical University.

Takashi Shimada (T)

Nippon Medical School.

Satoru Takahashi (S)

University of Tsukuba.

Kenzaburo Tani (K)

The University of Tokyo.

Yasutomo Nasu (Y)

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.

Tomoji Mashimo (T)

The University of Tokyo.

Hiroyuki Mizuguchi (H)

Osaka University.

Kohnosuke Mitani (K)

Saitama Medical University.

Kazushige Maki (K)

Pharmaceuticals and Medical Devices Agency.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH